Drug intelligence / Profile preview

alpha

Development stage: Preclinical
Lead developer: A-Alpha Bio
Modality: Small Molecules
Administration: Topical

Overview

Alpha ointment is a topical formulation investigated for the prevention and treatment of acute skin complications, such as dermatitis, pain, and burning, associated with radiotherapy in breast cancer patients. Clinical trials have shown it to be more effective than hydrocortisone 1% ointment in relieving pain and burning and preventing complications, with the exception of itching. It is suggested that alpha ointment, either alone or in combination with hydrocortisone 1%, could be a beneficial strategy to mitigate radiotherapy-induced skin injuries.

Beyond the preview

Go deeper on alpha.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpha.

Explore the full profile